MIZ1-mediated repression is required for tumor formation in MYC-driven lymphoma (van Riggelen et al., 2010) and medulloblastoma (Vo et al., 2016), suggesting that targeting the complex may provide a second strategy with a significant therapeutic window for MYC-dependent tumors. This evidence concerns the gene MYC and lymphoma.